Titan Pharmaceuticals (TTNP)
NASDAQ:TTNP
US Market

Titan Pharmaceuticals (TTNP) Income Statement

786 Followers

Titan Pharmaceuticals Income Statement

Last quarter (Q ), Titan Pharmaceuticals's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q, Titan Pharmaceuticals's net income was $-1.06M. See Titan Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 185.00K$ 1.00K$ 557.00K$ 1.28M$ 4.84M$ 2.60M
Cost of Revenue
---$ 199.00K$ 472.00K$ 0.00
Gross Profit
$ 87.00K$ 1.00K$ 557.00K$ -199.00K$ 4.37M$ 2.60M
Operating Expense
$ 878.00K$ 7.46M$ 10.79M$ 10.68M$ 11.72M$ 10.48M
Operating Income
$ -2.92M$ -7.28M$ -10.23M$ -10.88M$ -7.35M$ -7.88M
Net Non Operating Interest Income Expense
$ 19.00K$ 5.00K$ 53.00K$ 1.00K$ -769.00K$ -967.00K
Other Income Expense
$ -1.83M$ 1.70M$ 24.00K$ -2.10M$ 713.00K$ 1.35M
Pretax Income
$ 1.06M$ -5.57M$ -10.21M$ -8.78M$ -7.41M$ -7.49M
Tax Provision
-$ 11.00K$ -488.00K$ -3.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -1.07M$ -5.57M$ -10.21M$ -8.78M$ -18.24M$ -16.46M
Basic EPS
$ -1.37$ -7.41-$ -0.90$ -4.83$ -21.60
Diluted EPS
$ -1.48$ -7.41-$ -0.90$ -4.83$ -21.60
Basic Average Shares
$ 30.89M$ 752.00K-$ 9.73M$ 3.77M$ 765.23K
Diluted Average Shares
$ 45.90M$ 752.00K-$ 9.73M$ 3.77M$ 765.23K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 878.00K$ 7.46M$ 10.79M$ 10.88M$ 12.19M$ 10.48M
Net Income From Continuing And Discontinued Operation
$ -4.66M$ -5.57M$ -10.21M$ -8.78M$ -18.24M$ -16.46M
Normalized Income
$ -3.25M-$ -10.62M-$ -6.40M$ -8.83M
Interest Expense
----$ 769.00K$ 967.00K
EBIT
$ 1.03M$ -5.56M$ -10.21M$ -8.78M$ -7.35M$ -6.52M
EBITDA
$ 1.15M$ -5.42M$ -9.56M$ -8.52M$ -7.06M$ -6.28M
Currency in USD

Titan Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis